# Trade Mark Journal No.2026/014 3 April 2026

## UK00004355478 16 March 2026 (5,42)

CTX611

International priority date claimed: 7 January 2026 (United States of America) (99583006)

Class 5
  Cells for medical or clinical use in the field of gene therapy for the treatment of cardiovascular diseases and thromboembolic diseases and disorders; pharmaceutical and biopharmaceutical agents for the treatment of cardiovascular diseases and thromboembolic diseases and disorders in the field of gene therapy; gene therapy products, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of cardiovascular diseases and thromboembolic diseases and disorders in the field of gene therapy.
Class 42
  Gene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders in the field of in vivo gene editing therapy; gene editing, namely, pharmaceutical research and development in the field of gene therapy.

CRISPR Therapeutics AG

Representative: HGF Limited